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Abstract
Acrocallosal syndrome (ACLS) is an autosomal recessive neurodevelopmental disorder caused by KIF7 defects and belongs
to the heterogeneous group of ciliopathies related to Joubert syndrome (JBTS). While ACLS is characterized by
macrocephaly, prominent forehead, depressed nasal bridge, and hypertelorism, facial dysmorphism has not been emphasized
in JBTS cohorts with molecular diagnosis. To evaluate the speciﬁcity and etiology of ACLS craniofacial features, we
performed whole exome or targeted Sanger sequencing in patients with the aforementioned overlapping craniofacial
appearance but variable additional ciliopathy features followed by functional studies. We found (likely) pathogenic variants
of KIF7 in 5 out of 9 families, including the original ACLS patients, and delineated 1000 to 4000-year-old Swiss founder
alleles. Three of the remaining families had (likely) pathogenic variants in the JBTS gene C5orf42, and one patient had a
novel de novo frameshift variant in SHH known to cause autosomal dominant holoprosencephaly. In accordance with the
patients’ craniofacial anomalies, we showed facial midline widening after silencing of C5orf42 in chicken embryos. We
further supported the link between KIF7, SHH, and C5orf42 by demonstrating abnormal primary cilia and diminished
response to a SHH agonist in ﬁbroblasts of C5orf42-mutated patients, as well as axonal pathﬁnding errors in C5orf42-
silenced chicken embryos similar to those observed after perturbation of Shh signaling. Our ﬁndings, therefore, suggest that
beside the neurodevelopmental features, macrocephaly and facial widening are likely more general signs of disturbed SHH
signaling. Nevertheless, long-term follow-up revealed that C5orf42-mutated patients showed catch-up development and
fainting of facial features contrary to KIF7-mutated patients.
Introduction
Acrocallosal syndrome (ACLS; [MIM #200990]) is a neu-
rodevelopmental ciliopathy which was ﬁrst described in two
unrelated Swiss patients with intellectual disability (ID),
agenesis of the corpus callosum, craniofacial dysmorphism,
and polydactyly together with additional anomalies [1, 2].
In 2011, biallelic mutations of KIF7 [MIM *611254], a key
component of the Sonic Hedgehog (SHH) signaling path-
way, have been found as the genetic cause of ACLS and
fetal hydrolethalus syndrome [3]. Following the discovery
of the gene and description of further patients showing
overlapping features with Joubert syndrome (JBTS; [MIM
#213300]), ACLS has been listed under the designation of
the clinically and genetically heterogeneous Joubert
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syndrome-related disorders (JSRD) [4, 5]. Distinct cranio-
facial features of macrocephaly, prominent forehead, and
depressed/wide nasal bridge have been considered char-
acteristic of ACLS [1–3, 6, 7], but were also emphasized in
a fraction of molecularly undiagnosed JSRD cohorts [8–10].
Therefore, to study the speciﬁcity and etiology of the ACLS
craniofacial features, we evaluated 13 cases from 9 families
with the craniofacial appearance ﬁtting into the ACLS
spectrum as well as variable additional ciliopathy features
by whole-exome sequencing (WES) or targeted Sanger
sequencing of KIF7. Remarkably, 8 of the 9 families
showed either KIF7 or C5orf42 [MIM *614571] recessive
(likely) pathogenic variants, and in 1 patient we found a de
novo frameshift variant of SHH [MIM *600725] indicating
a shared role of these genes in craniofacial and neural
development. To date, C5orf42 has been reported as the
most common mutated gene in JBTS [11, 12] and the
related oral-facial-digital syndrome type VI (OFDVI) [13]
often presenting with polydactyly and ocular motor apraxia
beside the constant molar tooth sign (MTS)/vermis hypo-
plasia and ID/developmental delay (DD). Midline facial
defects such as notched upper lip, cleft lip/ palate, and
tongue hamartomas are additional features in OFDVI [13].
Since in contrast to KIF7 and SHH, the function of
C5orf42 was unknown, we evaluated the primary cilia and
their response to SHH agonist stimulation in ﬁbroblasts of
C5orf42-mutated patients, and assessed its role in devel-
opment by in ovo RNAi-mediated gene silencing in chicken
embryos. Our data provide the ﬁrst evidence for the
importance of C5orf42 in craniofacial development as well
as axon guidance and also suggest its functional link to
KIF7 and SHH through SHH signaling. Taken together, the
craniofacial features previously considered as characteristic
of ACLS appear to be a more general sign of disturbed SHH
signaling.
Subjects and Methods
Patients
We collected 13 cases from nine families including the
original ACLS cases reported by Schinzel et al. [2, 14],
presenting with relative/absolute macrocephaly, broad/pro-
minent forehead, depressed/wide nasal bridge and hyperte-
lorism as well as variable additional ciliopathy or ACLS
features including polydactyly, MTS/cerebellar vermis
hypoplasia, abnormal corpus callosum, oculomotor apraxia,
and notched upper lip (Table 1). Genetic testing was either
performed on a diagnostic basis with subsequent consent for
publication or as part of a research study approved by the
ethics commission of the Canton of Zurich.
Genetic studies
Genetic studies were performed on DNA extracted from
peripheral blood except for the deceased father of patient
13, in whom the DNA was extracted from shaving material
using the standard Chelex method [15]. In the latter, the
assumed probe relationship was conﬁrmed as described in
the Supplementary Materials and Methods. Targeted Sanger
sequencing of KIF7 (NM_198525.2, NG_030338.1) in
patients 2, 3, 9, 10, and 13, and the mother of patient 1 was
performed after PCR ampliﬁcation of all exons and ﬂanking
intronic nucleotides using an AB3730 capillary sequencer
(Applied Biosystems, Foster City, CA). Candidate nucleo-
tide variants from WES in C5orf42 (NM_023073.3,
NG_032772.1) and SHH (NM_000193.2, NG_007504.1)
were also conﬁrmed by Sanger sequencing. Variant
nomenclature, and variant classiﬁcation are based on the
HGVS recommendations (http://varnomen.hgvs.org/), and
ACMG guidelines [16], respectively. Chromosomal
microarray analysis in patients 2–5, 9–11, 13 and the
mother of patient 1, was performed using Affymetrix
Cytoscan HD arrays as described previously [17]. WES in
patients 4–12 was performed as described elsewhere with
minor modiﬁcations [18], or using the Agilent SureSelect
XT Clinical Research Exome Kit on a Illumina 2500 Sys-
tem (Illumina, San Diego, CA) in patient 13 and his mother.
The WES data of individual cases were analyzed using the
NextGENe Software (SoftGenetics, State College, PA) for
non-silent exonic and splice site variants considering both
dominant and recessive modes of inheritance. All variants
were submitted to ClinVar database (https://www.ncbi.nlm.
nih.gov/clinvar/) with ClinVar accessions SCV000579218,
SCV000579459-68, and SCV000579219 for KIF7,
C5orf42, and SHH, respectively. Variants of C5orf42
detected in patients 9–12 were also submitted to LOVD
database (www.LOVD.nl/C5orf42) with IDs of 00103650-
53, respectively.
We estimated the age of Swiss founder alleles using the
ESTIAGE software [19] (Supplementary Materials and
Methods) on haplotypes of patients 2 and 3, as well as two
previously published [7] Swiss patients.
Functional studies of C5orf42 in patient ﬁbroblasts
To assess the effect of the C5orf42 variants on primary cilia
and SHH signaling, standard skin-punch biopsies from
patients 11 and 12 with (likely) pathogenic C5orf42 var-
iants, their carrier parents and an unrelated control were
obtained and cultured according to standard protocols. We
quantiﬁed the number and length of primary cilia in the
ﬁbroblasts, and assessed their responsiveness to serum
starvation and stimulation with a SHH agonist, SAG, as
described in the Supplementary Materials and Methods.
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Fig. 1 Craniofacial features of patients with biallelic KIF7 or de novo
SHH variants. a–d Deceased female patient 1 at 2 years and 2 months
a–c and in adulthood d whose mother was shown to be a heterozygous
carrier of a KIF7 variant; e–h male patient 2 with pathogenic KIF7
biallelic Swiss founder variants at 3 months (e), 3 years (f) and 33
years (g, h) of age; i–l the previously reported male patient (case 4 of
Putoux et al. 2012) with the same biallelic variants as patient 2 at
the age of 3 months (i, j) and 26 years (k, l); m, n female patient 3
with KIF7 homozygous Swiss splice site pathogenic variants at
5 months (m) and 21 years of age (n); o–p male patient 13 with a de
novo SHH variant at 29 years. Note the shared facial features of
broad and high forehead, hypertelorism, ﬂat nasal root, thin upper and
everted lower lips, and retracted but relatively large chin. Patient 3
(m, n) shows the mildest dysmorphism corresponding with the
milder intellectual disability, likely due to the leakiness of the splice
site variant
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Functional studies of C5orf42 in chicken embryos
Gene silencing by in ovo RNAi
Loss-of-function phenotypes of C5orf42 were induced by in
ovo RNAi in chicken embryos as described before [20, 21]
through the injection of double-stranded RNA followed by
electroporation at Hamburger Hamilton (HH) [22] stages
HH10-12 (embryonic day (E) 1.5–2) and HH17-19
(E2.5–3) to target cranial neural crest cells (NCCs), and
dorsal commissural neurons (dI1) of the spinal cord,
respectively. Untreated embryos, and embryos electro-
porated with a green ﬂuorescent protein (GFP)-encoding
plasmid were used as controls. Double-stranded RNA was
Fig. 2 Clinical features of patients with C5orf42 biallelic variants. a–d
male patient 9 at 1 year 3 months (a–c) and 9.5 years (d); e–i female
patient 10 at 2 years 8 months (e), about 6.5 years (f) and about 14
years (h, i); j–k female patient 11 at about 2.5 (j) and 7.5 (k) years of
age; l–m patient 12 (brother of patient 11) at 8 months (l) and 6 years
(m) of age. Note the hallux duplication in patients 9 (c) and 10 (g) and
ACLS-like craniofacial features in all patients being more evident in
early childhood but becoming milder with time
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derived from two non-overlapping fragments of the
C5orf42 open reading frame (XM_015277526).
Analysis of dorsal commissural axon pathﬁnding
For analysis of commissural axon trajectories, embryos
were killed at HH25–26 (E5). The spinal cord was removed
from the embryo, opened at the roof plate (open-book
preparation) and ﬁxed [23]. The trajectories of dorsal
commissural axons (dI1) at the lumbar level of the spinal
cord were visualized using the lipophilic dye Fast-DiI
applied to the cell bodies [21]. Pathﬁnding behavior of dI1
commissural axons was categorized as “normal” when axons
crossed the midline and turned rostrally along the con-
tralateral ﬂoor-plate border, as “stalling” if at least 50% of
the axons failed to cross the midline, or as “no turn” if at
least 50% of the axons reaching the contralateral ﬂoor-plate
border failed to turn rostrally. The data from experimental,
control-injected, and untreated control embryos were com-
pared using analysis of variance followed by Tukey’s post-
hoc test accessed on the VassarStats Website for Statistical
Computation (http://vassarstats.net/).
Analysis of neural circuit formation in the peripheral
nervous system
For analysis of dorsal root ganglia (DRG) and dorsal roots,
sciatic nerve, and crural nerve, embryos were killed at
HH25–26 (E5) and stained as whole mounts using an anti-
neuroﬁlament antibody (RMO270; 1:1500; Invitrogen)
[22].
Analysis of craniofacial features
To analyze the role of C5orf42 in craniofacial development,
we silenced C5orf42 in cranial NCCs at HH10-12. Heads of
embryos killed at HH29 were incubated with Alcian Blue
solution (0.02% Alcian Blue in 80% ethanol, 20% acetic
acid) for 24 h at 4°C on an orbital shaker. The heads were
then transferred to pure ethanol for 5 days at 4°C to remove
excessive dye. After incubation overnight in 0.5% KOH and
several days in 1.8% KOH, heads were imaged with an
Olympus SZX12 stereo microscope.
Fig. 3 Evaluation of the primary
cilia and response to the SHH
agonist SAG in ﬁbroblasts of
patients 11 and 12 with
compound heterozygous (likely)
pathogenic variants in C5orf42
compared to the controls. a, b
Representative ﬁbroblast images
from a control and patient 12
immunostained for acetylated-α-
tubulin (green). c, d Fibroblast
cultures of the patients showed
signiﬁcantly fewer and shorter
primary cilia compared to those
of the controls. Results are
expressed as mean values± SD
(*P< 0.05, **P< 0.001,
Mann–Whitney). e, f qPCR
analysis of GLI1 and PTCH1
expression in control and patient
ﬁbroblasts following 48 h serum
starvation and subsequent 48 h
treatment with SAG. After
treatment, patient ﬁbroblasts
showed signiﬁcantly lower level
increase in the expression of
GLI1 and PTCH1 transcripts
compared to the controls.
Results are expressed as mean
values± SEM (*P< 0.05, **P
< 0.001, t test)
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Fig. 4 Silencing C5orf42 in the
developing neural tube of
chicken embryos resulted in
pathﬁnding errors of
commissural axons at the
midline. The pathﬁnding
behavior of dI1 commissural
axons at the ﬂoor plate was
analyzed in open-book
preparations of the spinal cord
(a; see Methods section for
details). Axonal trajectories (red)
are visualized by the injection of
DiI into the area of commissural
neuron cell bodies. In untreated
control embryos, commissural
axons grew ventrally, entered
the ﬂoor plate to cross the
midline and turned rostrally at
the ﬂoor-plate exit site (arrows,
b). No difference in
commissural axon pathﬁnding
was observed in control-treated
embryos (c). In contrast, after
silencing C5orf42 in the neural
tube, dI1 commissural axons
failed to cross the midline,
stalled in the ﬂoor plate (arrow
heads) and also failed to turn
rostrally along the contralateral
ﬂoor-plate border (open arrow,
d). The ﬂoor plate is indicated
by dashed lines. Bar: 50 µm.
Quantiﬁcation of phenotypes as
average percentage of DiI
injection sites per embryo with
the given phenotypes (e, shown
with SEM; *P< 0.05). Green
bars for untreated control
embryos, blue bars for control-
treated embryos-expressing
GFP, red bars for embryos after
RNAi-mediated silencing of
C5orf42 (LOF, loss-of-
function). In addition, silencing
C5orf42 in cranial neural crest
cells of developing chicken
embryos resulted in facial
dysmorphism. In comparison
with the control-treated embryos
(f), embryos lacking C5orf42 in
cranial neural crest cells
developed aberrant facial
features (g). The nasal structure
(arrowhead) was much wider
than in age-matched control
heads stained with Alcian Blue.
Similarly, the jaw was broader in
experimental compared to
control embryos (indicated by
black line) and eye distance was
increased
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Results
Genetic studies in the patients
Targeted Sanger sequencing or WES revealed homozygous
or compound heterozygous KIF7 pathogenic variants in 7
patients (patients 2–8). In the deceased patient 1, only the
DNA from the mother was available, who was conﬁrmed by
Sanger sequencing to be the carrier of a heterozygous KIF7
variant. By WES, we found compound heterozygous
(likely) pathogenic variants affecting C5orf42 in 4 patients
(patients 9–12), and a de novo frameshift variant affecting
SHH in 1 patient (patient 13). Summary of all the variants
and their classiﬁcation are available in Table 1 and Sup-
plementary Table S1.
Description of patients and variants
Patients 1 to 8 with ACLS harboring KIF7 variants
Patients 1–3 were the two original patients [1, 2] and a later
described case [14] with ACLS reported by Schinzel et al. in
1980 and 1988, respectively. Their follow-up clinical infor-
mation, morphological anomalies and sequencing results are
summarized in Table 1, Supplementary Results and Fig. 1.
We identiﬁed a heterozygous deletion of two amino acids in
the kinesin motor domain of KIF7 in the mother of patient 1,
as the only available family member. Patients 2 and 3 har-
bored the same two splice site and stop pathogenic variants
reported previously [7] in two other Swiss patients (one of
them depicted in Fig. 1i–l). Of note, all carriers of the splice
site variant (c.2593-3 C>G) originated from the Cantons of
Appenzell in Northeastern Switzerland, and those carrying the
stop variant (c.3001 C>T; p.(Gln1001*)) originated from the
Canton of Lucerne in central Switzerland (Supplementary
Fig. S1). We estimated the most recent common ancestor
(MRCA) of the c.2593-3 C>G variant, based on haplotype
sharing analysis of three variant-carrying haplotypes, to have
lived 159 generations ago (95% CI: 65–415), corresponding
to the point estimates of the mutational age of 2385, 3180, or
3975 years when assuming a generation time of 15, 20, or 25
years, respectively. The c.3001 C>T (p.(Gln1001*)) variant,
based on the analysis of ﬁve haplotypes, is estimated to be
much younger, with the MRCA to have lived 78 generations
(95% CI: 40–154) ago, translating into 1170–1950 years
before present with generation times between 15 and 25 years,
respectively.
Patients 4–5 and 6–8 were offsprings of consanguineous
parents harboring homozygous frameshift or stop variants in
KIF7 (Table 1), respectively, the former located within a
shared long stretch of homozygosity. Their clinical infor-
mation is summarized in Table 1, Supplementary Results
and Fig. S2.
Patients 9 to 12 with JBTS harboring C5orf42 variants
Both of these affected sib pairs (patients 9–10 and 11–12)
were offspring of non-consanguineous parents with com-
pound heterozygous variants in C5orf42. Their clinical
information, morphological anomalies and sequencing
results are summarized in Table 1, Supplementary Results
and Fig. 2. Notably, we found that C5orf42 biallelic mutant
ﬁbroblasts from patients 11 and 12 formed signiﬁcantly
fewer and shorter primary cilia compared to the control
ﬁbroblasts (P< 0.05, Mann–Whitney) (Fig. 3a–d). After
treatment with SAG, patient ﬁbroblasts showed sig-
niﬁcantly lower level increase in the expression of GLI1 and
PTCH1 transcripts compared to the controls (P< 0.05,
t test) (Fig. 3e–f)
Patients 13 harboring a SHH variant
Patient 13 was offspring of non-consanguineous parents and
was negative for KIF7 and C5orf42 variants but harbored a
previously unreported de novo frameshift variant in the last
exon (exon 3) of SHH. His clinical information, morpho-
logical anomalies, and sequencing result are summarized in
Table 1, Supplementary Results and Fig. 1o, p. This variant
causes a frameshift with introduction of a premature stop
codon, but affects the last 35 amino acids at C-terminal and
therefore likely does not lead to nonsense-mediated mRNA
decay. Nevertheless, the C-terminal portion of SHH is
essential for catalyzing the autocleavage of the protein to
the active N-terminal fragment, as well as additional post-
translational modiﬁcations [24], and therefore we assume
that the modiﬁed C-terminus interferes with these processes
leading to abnormal levels of active SHH. However, further
patients with similar phenotype and SHH variants are nee-
ded to clarify the signiﬁcance of this variant.
Functional analysis of C5orf42 in chicken embryos
To decipher the role of C5orf42 in neural and craniofacial
development, we evaluated the phenotypic changes fol-
lowing its silencing in chicken embryos. We found crucial
roles of C5orf42 in axonal pathﬁnding in the central ner-
vous system (CNS) (Fig. 4), and in the peripheral nervous
system (PNS) (Supplementary Fig. S3), as well as cranio-
facial development in accordance with the phenotypes seen
in the patients (Fig. 4h–j).
Silencing of C5orf42 interferes with the pathﬁnding of
commissural axons
In untreated and control-treated embryos commissural dI1
axons had crossed the midline and turned rostrally along the
contralateral ﬂoor-plate border at HH25–26 (Fig. 4a–c).
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After silencing C5orf42 the initial growth of dI1 axons
towards the ﬂoor plate was not different from controls and
axons reached the ventral midline of the neural tube at the
appropriate time. However, in experimental embryos axons
either failed to cross the midline or to turn rostrally along
the contralateral border of the ﬂoor plate (Fig. 4d, e). On
average, we found axonal stalling at 22.7± 4.9% of the
injection sites in C5orf42-deﬁcient embryos, compared to
2.7± 1.4 and 1.8± 1.0% in untreated and GFP-expressing
controls, respectively. Furthermore, the failure of dI1 axons
to turn rostrally along the contralateral ﬂoor-plate border
was observed at an average of 42.9± 5.9% of the injection
sites after C5orf42-silencing compared to 9.7± 4.3% and
26.6± 5.3% in the untreated and GFP-expressing controls,
respectively. Overall, after silencing of C5orf42, on average
only 44.6± 5.7% of the analyzed injection sites per embryo
showed normal axon guidance which was signiﬁcantly
lower than the 86.2± 4.0% in untreated (P< 0.05) and 72.3
± 5.2% in GFP-expressing controls (P < 0.05) (Fig. 4e).
Silencing C5orf42 affects neural circuit formation in PNS
After silencing C5orf42, the size and arrangement of DRG,
the number of dorsal roots, and the branching of sciatic
nerves were perturbed in embryos analyzed at HH25–26
(Supplementary Fig. S3). After loss of C5orf42 function,
DRG were of variable shape and size, and they were
arranged asymmetrically in >90% of the embryos (Sup-
plementary Fig. S3B, G). In addition, adjacent DRG were
connected by ﬁbers or had joint roots, aberrant phenotypes
that were not observed in control embryos (Supplementary
Fig. S3C).
Neural circuits in the limbs were compromised in the
absence of C5orf42. In control embryos, the dorsal branch
of the sciatic nerve segregated into an anterior and a pos-
terior branch of about the same thickness (Supplementary
Fig. S3D). In contrast, experimental embryos showed
aberrant sciatic nerve branching (Supplementary Fig. S3E).
Silencing of C5orf42 in cranial NCCs leads to abnormal
facial features in chicken embryos
After silencing C5orf42 in cranial NCCs, embryos devel-
oped aberrant facial features compared to controls
(Fig. 4f–g). The distance between the eyes was increased,
their nasal structure and their jaw were much wider com-
pared to the age-matched controls.
Discussion
Genetic analysis in our cohort of patients with craniofacial
appearance ﬁtting into the ACLS clinical spectrum and
variable additional ciliopathy features revealed (likely)
pathogenic variants not only in KIF7, but also secondly in
C5orf42, the most commonly mutated gene in JBTS [11,
12] and the related OFDVI [13]. In addition, in one patient
we found a heterozygous de novo frameshift variant in
SHH, the most common cause of non-chromosomal holo-
prosencephaly (HPE) [25, 26]. All our patients shared ID,
relative or absolute macrocephaly, prominent/broad fore-
head, depressed/wide nasal bridge, hypertelorism, and brain
anomalies of either abnormal corpus callosum or MTS or
vermis hypoplasia. However, long-term follow-up revealed
that patients with pathogenic KIF7 variants had more severe
and persistent facial dysmorphism and in general more
severe ID, while in patients with (likely) pathogenic
C5orf42 variants, facial dysmorphism became less promi-
nent over time and they could catch up and reach a level of
mild to moderate ID despite initial severe DD. Importantly,
patient 3 with homozygosity of the KIF7 splice site
pathogenic variant at position −3 could also catch up with
only mild cognitive deﬁcits in adulthood, which may indi-
cate some leakiness of this variant. Notably, C5orf42
(likely) pathogenic variants are nearly invariably associated
to the MTS/vermis hypoplasia and less often to corpus
callosum abnormalities, while it is the opposite for KIF7. In
addition, none of the KIF7 patients but all the C5orf42
patients in our cohort presented with ocular motor apraxia,
which is commonly associated with the MTS in JBTS
patients (Table 2 and Supplementary Table S2) [12, 27, 28].
Consistent with previous reports [3, 7, 11, 13, 29], we
Table 2 Frequency of major clinical features in patients with
recessive KIF7 or C5orf42 variants from the literature and this study
Clinical feature KIF7-positive
ACLS/ JBTS
C5orf42-positive
JBTS/ OFDVI
(Relative) Macrocephaly 28/34 (82%) 5/5 (100%)
Prominent/broad forehead 34/38 (89%) 9/9 (100%)
Hypertelorism 34/37 (92%) 7/8 (88%)
Depressed/wide nasal
bridge
33/34 (97%) 6/6 (100%)
Polydactyly 26/41 (63%) 37/71 (52%)
Abnormal corpus
callosum
38/40 (95%) 6/13 (46%)
MTS/VH 18/32 (56%) 77/77 (100%)
Developmental delay/ID 40/41 (98%) 36/36 (100%)
Seizure 7/18 (39%) 2/19 (11%)
Ocular motor apraxia 0/9 (0%) 27/38 (71%)
Nystagmus/strabismus 9/18 (50%) 13/21 (62%)
JBTS breathing
abnormalities
1/10 (10%) 14/28 (50%)
ACLS acrocallosal syndrome, JBTS Joubert syndrome, OFDVI oral-
facial-digital syndrome type VI
MTS molar tooth sign, VH vermis hypoplasia, ID intellectual disability
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observed polydactyly in half or more of the patients with
KIF7 or C5orf42 pathogenic variants, which especially
highlights the association of C5orf42 with polydactyly
among JBTS genes. This observation also provides the
clinical evidence for the possible function of C5orf42 in
SHH signaling due to the well-known role of SHH pathway
in limb development and association of human congenital
limb defects to the defective pathway [30].
It was also remarkable that among our KIF7-positive
cases, two of the Swiss patients harbored identical mutated
alleles to the two previously reported Swiss patients [7].
Evaluation of their origin revealed the carriers of the splice
site variant (c.2593-3 C>G) to come from the Cantons
Appenzell in Northeastern Switzerland and those of the stop
variant c.3001 C>T (p.(Gln1001*)) from the Canton
Lucerne in central Switzerland. The estimated age of the
two variants dates back to only about 2000–4000 and
1000–2000 years, respectively, corroborating their status as
Swiss founder alleles. Both regions were apparently
inhabited by Celtic tribes called Räter and Helvetier,
respectively.
KIF7 is well known for its role in the regulation of Shh
signaling in primary cilia which is crucial for limb devel-
opment, tissue patterning and growth of brain structures
during embryogenesis [24, 31–33]. In contrast, the protein
encoded by C5orf42 has remained grossly uncharacterized.
Because of its classiﬁcation as a ciliopathy gene, we eval-
uated the primary cilia in ﬁbroblasts of two patients with
biallelic variants of C5orf42 which revealed signiﬁcantly
fewer and shorter cilia. We also observed signiﬁcantly
diminished response of these ﬁbroblasts to the SHH agonist
SAG, indicating that C5orf42 is required for efﬁcient SHH
signaling. In addition, silencing C5orf42 during neural
development of chicken embryos revealed very similar
phenotypes in commissural axon guidance to those
observed after silencing Shh signaling [34, 35] which are
compatible with compromised ciliary function.
Our ﬁndings of aberrant midline crossing in the CNS
suggests a contribution of C5orf42-related ciliary signaling
to neural circuit formation, which may explain the patho-
mechanism of the neurodevelopmental features seen in the
patients. Although the role of ciliary signaling in neural
circuit formation in the PNS has not been studied so far, our
studies suggest that the mechanisms are conserved between
CNS and PNS. This is in line with current knowledge in the
axon guidance ﬁeld that axon guidance cues and their
receptors, as well as the signaling mechanisms are con-
served between CNS and PNS [36]. Though, nothing is
known about aberrant development of the PNS in patients,
the observed changes in PNS wiring in the chicken embryo
could indicate that the wiring problems also occur in the
patients, where they could contribute to the observed motor
problems.
Our ﬁndings are also in line with recent data from a
mouse model harboring the C5orf42 S235P mutation,
locating the protein to the cilia transition zone and indi-
cating a reduced Shh response to SAG, as well as dimin-
ished number of cilia in mutated mouse embryonic
ﬁbroblasts, and absent cilia in ﬁbroblasts of a patient with
compound heterozygous C5orf42 variants [37]. Accord-
ingly, the overlapping phenotype of C5orf42 and KIF7-
mutated patients may be explained by their shared role in
ciliary-dependent SHH signaling. This assumption is further
supported by the de novo SHH variant in patient 13 with
similar craniofacial features and agenesis of the corpus
callosum. However, direct conclusion for the positive/
negative role of C5orf42 in regulating SHH signaling can-
not be made especially based on the response of the
C5orf42-mutated ﬁbroblasts to the SAG agonist, since the
repression of the pathway, though variable, would be
expected to result in the narrowing of facial midline [26,
38]. This discrepancy could be due to the spatial and tem-
poral dynamics of the pathway during development or dif-
ferences in SHH responsiveness for the SAG agonist and
SHH. Similar inconsistency has been reported for induction
of Gli1 expression by SAG treatment in mouse embryonic
ﬁbroblasts derived from Kif7–/– mice [39].
For SHH, diverse missense and truncating variants have
been reported as the most common cause of non-
chromosomal HPE of different types with signiﬁcant
variability of penetrance and expressivity of unknown rea-
son [25, 26]. Therefore, although the pathogenicity of the
SHH terminal frameshift variant in patient 13 may be
questioned by the lack of typical HPE features, similar
contrasting phenotypes have been observed for PTCH1
encoding the SHH receptor. While most, probably loss-of-
function variants of PTCH1 lead to the nevoid basal cell
carcinoma (Gorlin) syndrome manifesting with macro-
cephaly, hypertelorism and abnormal corpus callosum,
some, probably activating missense variants cause HPE
[40–42]. Accordingly, we suggest that some speciﬁc var-
iants in SHH may mimic an ACLS phenotype.
Despite the fact that craniofacial features such as frontal
prominence and broad nasal bridge have been described in a
fraction of patients with JSRD [8–10], they have been less
carefully documented in those with molecular diagnosis
including patients with pathogenic C5orf42 variants
(Table 2 and Supplementary Table S2). Our ﬁndings, in
fact, highlight the overlapping craniofacial appearance of
macrocephaly, prominent/broad forehead, depressed/wide
nasal bridge, and hypertelorism among patients with (likely)
pathogenic KIF7 and C5orf42 variants. Moreover, this
clinical observation was strikingly replicated by facial
midline widening after knock-down of C5orf42 in cranial
NCCs of chicken embryos. Cleft lip, cleft palate, and
micrognathia have been previously observed in the S235P
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mutant mice [37], corresponding to cleft lip and palate in
OFDVI patients [13, 43]. Taken together, it is likely that the
aforementioned craniofacial features are due to the dis-
turbed role of KIF7 and C5orf42 in ciliary function
affecting SHH signaling, and possibly other pathways. The
latter may partly explain the differences in the ciliopathy
phenotypes.
In summary, our ﬁndings imply shared minimal diag-
nostic criteria among patients with biallelic (likely) patho-
genic variants of KIF7 or C5orf42, or certain variants of
SHH. In addition, we demonstrate the ﬁrst experimental
evidence for the role of C5orf42 in craniofacial develop-
ment as well as axon guidance and neural circuit formation.
Most likely, the effect of C5orf42 is mediated by primary
cilia function, required among others in the SHH signaling
pathway. Further studies will be needed to decipher the
interaction partners of C5orf42 and to characterize its
function in ciliary protein networks as well as ciliary-
dependent axon guidance.
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